422P Primary lung tumour laterality, molecular characteristics, and prognostic impact in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) in the phase III CASPIAN trial

comparisons between subgroups difficult.Limitations of this meta-analysis included heterogeneity of study populations and follow-up durations. Conclusions:This meta-analysis demonstrates the comparability in efficacy and safety of PD-(L)1 inhibitors for 1L ES-SCLC in both Asian and non-Asian pts.More realworld evidence at the regional level will confirm long-term clinical benefits and tolerability in specific pt populations.